Evidence That Drives Better Health Decisions.
In-depth research reviews, clinical insights, and data-driven analysis on supplements, healthspan, and healthy aging.
Explore What Matters Most
Cognitive Health
Memory, focus, mood, and brain aging.
Energy & Longevity
Cellular energy, NAD+, mitochondria, and longevity.
Immune Health
Immune function, resilience, and healthy aging.
Joints & Mobility
Cartilage, joint comfort, and mobility support.
Gut Health
Microbiome balance, digestion, and gut barrier.
Sleep & Stress
Sleep quality, stress response, and recovery.
Hormonal & Metabolic
Hormone balance, blood sugar, and metabolism.
Skin & Anti-Aging
Collagen, elasticity, and healthy aging.
Heart & Circulation
Cardiovascular health, blood flow, and lipids.
Longevity Pathways
Cellular aging, resilience, and healthspan.
New Evidence. New Insights.
EPA vs DHA: Differential Effects on Cardiometabolic Health
A comprehensive review of how EPA and DHA affect inflammation, lipids, endothelial function, and cardiometabolic outcomes.
NAD+ Boosters and Healthy Aging: An Updated Review
Examining NMN, NR, and related compounds for NAD+ elevation, clinical evidence, and safety.
Creatine for Brain, Muscle, and Healthy Aging
Beyond performance: emerging research on creatine's role in cognition, aging, and overall healthspan.
Peptide Status & Safety Explainers
BPC-157 FDA status: approval, compounding, and safety signals
BPC-157 removed from 503A/B compounding in 2024 — not FDA-approved for wellness. What the FDA safety-risk determination says and why the July 2026 PCAC review matters.
FDA peptide reclassification in 2026: what changed and what did not
BPC-157, TB-500, and others removed from legal compounding 2024–2026. Which were banned, which restricted, and what the PCAC review means — plainly.
Peptide safety: what the evidence actually says
Unapproved research peptides carry real risks — contamination, immunogenicity, and no long-term human trial data. Here is what the evidence says.
Peptides vs supplements: what is the difference?
Peptides span four legal categories — approved drug to research chemical. Understanding which category applies changes what safety data exists.
TB-500 FDA status: thymosin beta-4 fragment safety and evidence
TB-500 has no adequate human exposure data per the FDA — withdrawn from compounding and flagged at the July 2026 PCAC review. Safety signals explained.
Rigor. Transparency. Independence.
Comprehensive Search
Across databases
Evidence Evaluation
Quality and bias
Clinical Context
Real-world relevance
Safety First
Interactions and dosing
Expert Review
No brand influence
Stay Current with New Research
We add new research reviews every week. Get the latest evidence straight to your inbox.
Research Glossary
Understand key terms, study designs, and statistical concepts.
Last updated May 16, 2026 · New research added weekly